Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [134]

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy i...

Prof Barbara Eichhorst - University of Cologne, Cologne, Germany

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA

Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )

Spotlight on global cancer control at ASCO 2022

Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM

Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )

UICC announces global coalition to increase access to essential cancer medicines...

Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )

ASCO 2022: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2022: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosf...

Dr Julie Gralow- Chief Medical Officer, ASCO

$Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )$

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for...

Dr Martin McCabe- University of Manchester, Manchester, England

$Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Martin McCabe- University of Manchester, Manchester, England )$

High-dose ifosfamide standard of care for recurrent and primary refractory ewing...

Dr Martin McCabe - University of Manchester, Manchester, England

$High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )$

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovia...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial ...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

Renal liposarcoma: Case report and review of systemic treatment

Dr Abel Centurion - Peruvian National Cancer Institute, Surquillo, Peru

Renal liposarcoma: Case report and review of systemic treatment ( Dr Abel Centurion - Peruvian National Cancer Institute, Surquillo, Peru )

More from ecancer